Papp K - Search Results

1

Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.

Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, Murray E, Papp K, Poulin Y, Zip C. Guenther L, et al. Among authors: papp k. J Cutan Med Surg. 2004 Sep-Oct;8(5):321-37. doi: 10.1007/s10227-005-0035-1. J Cutan Med Surg. 2004. PMID: 15868311

2

Systemic gold therapy.

Papp KA, Shear NH. Papp KA, et al. Clin Dermatol. 1991 Oct-Dec;9(4):535-51. doi: 10.1016/0738-081x(91)90083-w. Clin Dermatol. 1991. PMID: 1822410 Review. No abstract available.

3

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, Beard A, Puvanarajan L, Paul C. Ho VC, et al. Among authors: papp ka. J Am Acad Dermatol. 2001 Apr;44(4):643-51. doi: 10.1067/mjd.2001.112400. J Am Acad Dermatol. 2001. PMID: 11260540 Clinical Trial.

4

Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea.

Tan JK, Girard C, Krol A, Murray HE, Papp KA, Poulin Y, Chin DA, Jeandupeux D. Tan JK, et al. Among authors: papp ka. J Cutan Med Surg. 2002 Nov-Dec;6(6):529-34. doi: 10.1007/s10227-001-0144-4. Epub 2002 May 13. J Cutan Med Surg. 2002. PMID: 12001006 Clinical Trial.

5

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.

Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A. Papp KA, et al. J Am Acad Dermatol. 2003 Jan;48(1):48-54. doi: 10.1067/mjd.2003.130. J Am Acad Dermatol. 2003. PMID: 12522370 Clinical Trial.

6

Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator.

Papp KA. Papp KA. Drugs Today (Barc). 2004 Nov;40(11):889-99. doi: 10.1358/dot.2004.40.11.872578. Drugs Today (Barc). 2004. PMID: 15645002 Review.

7

Potential future therapies for psoriasis.

Papp KA. Papp KA. Semin Cutan Med Surg. 2005 Mar;24(1):58-63. doi: 10.1016/j.sder.2005.01.005. Semin Cutan Med Surg. 2005. PMID: 15900800 Review. No abstract available.

8

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.

Bissonnette R, Papp K, Poulin Y, Lauzon G, Aspeslet L, Huizinga R, Mayo P, Foster RT, Yatscoff RW, Maksymowych WP; ISA247 Psoriasis Study Group. Bissonnette R, et al. Among authors: papp k. J Am Acad Dermatol. 2006 Mar;54(3):472-8. doi: 10.1016/j.jaad.2005.10.061. Epub 2006 Jan 23. J Am Acad Dermatol. 2006. PMID: 16488299 Clinical Trial.

9

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.

Papp KA, Ho V, Langley R, Lynde C, Poulin Y, Shear N, Toole J, Zip C. Papp KA, et al. J Cutan Med Surg. 2006;9 Suppl 1:26-32. doi: 10.1007/s10227-006-0104-0. J Cutan Med Surg. 2006. PMID: 16633859 Review.

10

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.

Langley RG, Ho V, Lynde C, Papp KA, Poulin Y, Shear N, Toole J, Zip C. Langley RG, et al. J Cutan Med Surg. 2006;9 Suppl 1:18-25. doi: 10.1007/s10227-006-0103-1. J Cutan Med Surg. 2006. PMID: 16633860 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

706 results

Search Page